期刊文献+

万古霉素在患儿治疗中给药剂量与谷浓度的评估 被引量:9

Evaluation of vancomycin dosing for treatment of children and trough concentration
原文传递
导出
摘要 目的评价万古霉素常用的两个剂量在患儿治疗中的药效学和安全性,及其谷浓度的最佳水平,以期为临床更合理的使用和监测万古霉素提供参考。方法以2012年7月-2014年12月医院接受万古霉素40 mg/(kg·d)(低剂量组)或60mg/(kg·d)(高剂量组)且进行血药浓度监测的患儿作为研究对象,观察两组患儿的不良反应;通过群体药动学模型计算AUC0-24h;采用SPSS 18.0软件对数据进行统计分析。结果低、高剂量组平均AUC0-24h分别为(326.7±284.5)mg·h/L和(472.3±399.1)mg·h/L,差异有统计学意义(P<0.05);分别有21.7%和56.7%的患儿AUC0-24h>400mg·h/L;两组患儿的不良反应差异无统计学意义;谷浓度和AUC0-24h相关性良好(P<0.01),谷浓度为10mg/L时,所有患儿均可达到AUC0-24h>400mg·h/L。结论在患儿中,万古霉素60mg/(kg·d)的初始剂量较40 mg/(kg·d)能获得更好的临床效果,且不增加其不良反应,当MIC≤1mg/L,谷浓度为10mg/L时,即可达到AUC0-24h/MIC>400mg·h/L的治疗水平。 OBJECTIVE To evaluate the pharmacodynamics and safety of two commonly used dosages of vancomycin on treatment of children and determine the optimal trough concentration so as to provide guidance for reasonable clinical use and surveillance of vancomycin.METHODS The children who were treated with 40mg/(kg·d)of vancomycin(the low-dose group)or 60mg/(kg·d)of vancomycin(the high-dose group)and received the surveillance of blood concentrations from Jul 2012 to Dec 2014 were recruited as the study objects,then the adverse reactions in the children were observed,the AUC0-24 hwas calculated by means of population pharmacokinetics model,and the statistical analysis of data was performed with the use of SPSS18.0software.RESULTS The mean AUC0-24 h was(326.7±284.5)mg·h/L in the low-dose group,(472.3±399.1)mg·h/L in the high-dose group,and there was significant difference(P0.05).The children with the AUC0-24 hmore than 400mg·h/L accounted for 21.7%in the low-dose group and accounted for 56.7%in the high-dose group.There was no significant difference in the incidence of adverse reactions between the two groups of children.The trough concentration was highly correlated with the AUC0-24 h,when the trough concentration was 10 mg/L,the AUC0-24 hwas more than 400mg·h/L for all the children.CONCLUSION As compared with the starting dose of 40mg/(kg·d),the initial dose of vancomycin 60mg/(kg·d)can achieve more significant effect on treatment of the children without the increase of incidence of adverse reactions.When the MIC is no more than 1mg/L and the trough concentration is 10mg/L,the target AUC0-24h/MIC400mg·h/L can be achieved.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2016年第6期1393-1396,共4页 Chinese Journal of Nosocomiology
基金 湖北省卫生厅科研基金资助项目(JX5B74) 武汉市科技攻关基金资助项目(2013060602010258)
关键词 万古霉素 儿童 剂量 谷浓度 Vancomycin Child Dose Trough concentration
  • 相关文献

参考文献3

二级参考文献22

  • 1Sievert D M, Rudrik J T, Patel J B, et al. Vancomycin-resistant Staphylococcus anreus in the United States, 2002 - 2006 [ J 1. Clin In- fect Dis, 2008, 46 (5) : 668 - 674. 被引量:1
  • 2Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-van- comycin-intermediate Staphylococcus aureus (VISA) tible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 -05 [J]. J Antimicmb Chemother, 2007, 60(4) : 788 -794. 被引量:1
  • 3Wang G, Hindler J F, Ward K W, et al. Increased vaneomycin MICs for Staphylococcus anreus clinical isolates from a university hospital dur- ing a 5-year period [ J ]. J Clin Microbiol, 2006, 44 ( 11 ) : 3883 - 3886. 被引量:1
  • 4Hawser S P, Bouchillon S K, Hoban D J, et al. Rising incidence of Staphylococcus anreus with reduced susceptibility to vaneomycin and susceptibility to antibiotics : a global analysis 2004 - 2009 [ J ]. Int J Antimicrob Agents, 2011, 37(3): 219-224. 被引量:1
  • 5Ho P L, Lo P Y, Chow K H, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong[ J ]. J Infect, 2010, 60(2) : 140 - 145. 被引量:1
  • 6Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing (CLSI document M100-S18 ) [ S. Wayne: Clinical and Laboratory Standards Institute, 2008:46 -53. 被引量:1
  • 7Sader H S, Fey P D, Fish D N, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep ) against methicillin-resistant Staphylococcus aureus isolates collected in nine U. S. medical centers from 2002 to 2006 [ J ] Antimicrob Agents Chemother, 2009, 53 (10) : 4127 -4132. 被引量:1
  • 8Lodise T P, Graves J, Evans A, et al. Relationship between vanco- mycin MIC and failure among patients with methicillin-resistant Staph- ylococcus anreus bacteremia treated with vancomycin [ J ]. Antimicrob Agents Chemother, 2008, 52(9) : 3315 -3320. 被引量:1
  • 9Soriano A, Marco F, Martinez J A, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin- resistant Staphylococcus aureus bacteremia [ J ]. Clin Infect Di% 2008, 46(23) : 193 -200. 被引量:1
  • 10Reynolds R, Hope R, Warner M, et al. Lack of upward creep of gly- copeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and h'eland 2001-07 [ J]. J Antimicrob Chemother, 2012, 67(12): 2912-2918. 被引量:1

共引文献777

同被引文献63

引证文献9

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部